Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities
R Ribeiro, MJ Carvalho, J Goncalves… - Frontiers in Molecular …, 2022 - frontiersin.org
Triple-negative breast cancer (TNBC) is a clinically aggressive subtype of breast cancer that
represents 15–20% of breast tumors and is more prevalent in young pre-menopausal …
represents 15–20% of breast tumors and is more prevalent in young pre-menopausal …
Targeting MSS colorectal cancer with immunotherapy: are we turning the corner?
Introduction Immunotherapy with checkpoint inhibition has shown potent antitumor activity in
patients with microsatellite instability (MSI) metastatic cancer. Microsatellite stable (MSS) …
patients with microsatellite instability (MSI) metastatic cancer. Microsatellite stable (MSS) …
Cell-based immunotherapies in gynecologic cancers
SM Lang, O Dorigo - Current Opinion in Obstetrics and …, 2022 - journals.lww.com
Cell-based immunotherapies in gynecologic cancers : Current Opinion in Obstetrics and
Gynecology Cell-based immunotherapies in gynecologic cancers : Current Opinion in Obstetrics …
Gynecology Cell-based immunotherapies in gynecologic cancers : Current Opinion in Obstetrics …